Examination of asprosin and klotho hormone levels in patients with lung cancer

Lung cancer continues to be one of the leading causes of cancer-related deaths globally. The development of lung cancer is thought to be the result of the interaction of many environmental and genetic factors. Despite numerous molecular and biochemical studies on the diagnosis and treatment of lung cancer in recent years, lung cancer-related deaths continue to increase. Since early diagnosis of lung cancer increases the chances of treatment, it is of great importance to investigate new biomarkers in diagnosis and treatment. Therefore, this study was conducted to determine the potential of asprosine and klotho as a new biomarker for the diagnosis of lung cancer in lung cancer patients. Blood samples were obtained from 40 patients with lung cancer diagnosed by PET CT and 40 healthy individuals. The levels of asprosine and klotho in the serum samples were analysed by ELISA kit method. Biochemical analyses (ALT, AST, CRP etc.) were performed by autoanalyser. The data obtained were analysed by SPSS. As a result of the study, asprosin level was found to be significantly lower in the lung cancer group compared to the control group, while klotho level was found to be significantly higher. The data obtained as a result of the study show that asprosin and klotho have the potential to be used in the early diagnosis of lung cancer by extracting disease-specific findings, so we hope that new studies with a large number of samples in different cancer stages will provide innovations in the diagnosis and treatment of lung cancer.